Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the ...

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

To confirm the hypothesis that concurrent menopause hormone therapy enhances the effectiveness of tirzepatide for weight loss in postmenopausal women, researchers conducted a real-world study using ...

Findings showed tirzepatide was superior to semaglutide for both the primary endpoint and all key secondary endpoints at 72 weeks. Average weight loss in the tirzepatide group was 20.2% compared ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Zepbound (tirzepatide) and Wegovy (semaglutide) both support weight loss by targeting hormones that influence appetite and metabolism. However, their mechanisms differ significantly.

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.